Quantitative Systematic Strategies LLC acquired a new stake in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) during the second quarter, Holdings Channel reports. The institutional investor acquired 63,918 shares of the biotechnology company’s stock, valued at approximately $186,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of BCRX. Amici Capital LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter valued at about $283,000. A.R.T. Advisors LLC increased its position in BioCryst Pharmaceuticals by 432.1% in the first quarter. A.R.T. Advisors LLC now owns 418,308 shares of the biotechnology company’s stock valued at $1,183,000 after buying an additional 339,688 shares in the last quarter. Renaissance Technologies LLC increased its position in BioCryst Pharmaceuticals by 104.5% in the first quarter. Renaissance Technologies LLC now owns 292,221 shares of the biotechnology company’s stock valued at $827,000 after buying an additional 149,318 shares in the last quarter. VHCP Management II LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter valued at about $13,271,000. Finally, HBK Investments L P increased its position in BioCryst Pharmaceuticals by 152.7% in the first quarter. HBK Investments L P now owns 49,773 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 30,073 shares in the last quarter. 70.32% of the stock is currently owned by hedge funds and other institutional investors.
Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded down 1.24% during mid-day trading on Monday, reaching $3.99. The company had a trading volume of 639,736 shares. The firm’s market capitalization is $294.06 million. The stock has a 50 day moving average of $4.41 and a 200-day moving average of $3.61. BioCryst Pharmaceuticals Inc. has a one year low of $1.63 and a one year high of $10.98.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. The firm had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $3.92 million. BioCryst Pharmaceuticals had a negative net margin of 285.24% and a negative return on equity of 187.98%. The company’s revenue was down 81.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.06 earnings per share. Equities analysts predict that BioCryst Pharmaceuticals Inc. will post ($1.03) EPS for the current year.
Several research firms have issued reports on BCRX. Piper Jaffray Cos. raised BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $5.00 to $8.00 in a report on Friday, August 12th. FBR & Co reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 8th. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $8.22.
In other BioCryst Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of the business’s stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $5.00, for a total transaction of $20,232,950.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Alane P. Barnes sold 8,357 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $4.27, for a total transaction of $35,684.39. Following the sale, the vice president now directly owns 79,377 shares in the company, valued at approximately $338,939.79. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.